Survival No Better With Intensive Surveillance in Endometrial Cancer
An intensive surveillance regimen for endometrial cancer did not improve overall survival (OS) over a minimalist regimen, even in high-risk patients, results from the randomized TOTEM trial showed. After a median follow-up of 69 months, the 5-year OS rate was 90.6% with the intensive approach versus 91.9% with the minimalist approach, which mainly included physical […]
Pathogens Head for Surgical Helmets During Orthopedic Surgeries
Bacterial colonization of surgical helmets, a prophylactic aspirin regimen for venous thromboembolism (VTE), and the value of virtual visits in pediatric orthopedics were examined in several studies at the American Academy of Orthopaedic Surgeons meeting. Pathogens and Surgical Helmets Nearly three-fourths of a sample of surgical helmets and surgeons’ foreheads swabbed after a day’s worth […]
Simpler Antifungal Course Works for Cryptococcal Meningitis in Africa
A single high-dose course of liposomal amphotericin B as part of a three-drug antifungal treatment regimen was non-inferior to the current WHO-backed antifungal drug regimen for cryptococcal meningitis in people living with HIV, according to a phase III trial. In an intention-to-treat (ITT) analysis of 814 patients, 101 deaths were reported in the intervention group […]
Paired Anti-Obesity Drugs May Help Teens Shed More Weight After Metabolic Surgery
An add-on oral anti-obesity regimen may bolster bariatric surgery-induced weight loss in teens, a researcher reported. In a pilot study of 10 patients, adolescents who were placed on standard of care plus phentermine (Lomaira, Adipex-P) and topiramate (Trokendi XR, Qudexy XR, and Topamax) saw an average 4.3-point drop in BMI after 12 weeks compared with […]
Early Promise for Pembrolizumab Plus Chemo in RR Hodgkin’s Lymphoma
A chemoimmunotherapy regimen led to a 100% response rate as second-line therapy for relapsed/refractory (RR) classical Hodgkin lymphoma (cHL), a small phase II trial showed. All 38 evaluable patients achieved objective responses with the combination of pembrolizumab (Keytruda), gemcitabine, vinorelbine, and liposomal doxorubicin (P-GVD), including complete responses in 36 of 38 cases. All but two […]